Information
Reserpine Reserpine is an inhibitor of multidrug efflux pumps, used as an antipsychotic and antihypertensive drug. Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).
In vitro
Reserpine inhibits efflux pumps and reduces sparfloxacin, moxifloxacin and ciprofloxacin IC50s and MICs by up to four-fold in 11, 21 and 48 of the 102 unrelated clinical isolates tested.
In vivo
Reserpine (5 mg/kg s.c.) reduces extracellular DA levels to 4% of basal values in intact rats. Reserpine (5 mg/kg s.c.) diminishes L-DOPA (50 mg/kg i.p.)-induced increases in extracellular dopamine levels to 16% of those obtained in denervated animals not pretreated with reserpine in 6-hydroxydopamine-lesioned rats. Reserpine causes a marked depletion of Vasotocin/oxytocin-neu-rophysin-like immunoreactivity (LI) and CRH-L1 in the median eminence of the rat. Reserpine significantly restores performance on the delayed response task in monkeys. Reserpine has little effect on performance of a visual discrimination task, a reference memory task which does not depend on the prefrontal cortex. Reserpine injection (one dose of 1 mg/kg s.c.) every other day for 3 days causes a significant increase in vacuous chewing, tongue protrusion and duration of facial twitching in rats, compared to the control. Reserpine results in a decreased glutamate uptake in the subcortical parts of rats. Reserpine (5 mg/kg) significantly increases vacuous jaw movements, and also reduces rearing behavior in all age groups of rats.
Cell Data
cell lines：Prostate(LNCap,PC3), Cervix(HeLa), Pancreas(ASPC1), Sarcoma(Saos-2)Ovary(OVCAR8), Stomach(NCI-N87), Melanoma(SKMEL3,A431, MALME3M), Colon(Colo205,SW620,HCT116), Breast(SKBR3,MDA-MB-453,MCF7), Lung(NCI-H82,MV522,NCI-H522), etc.
Concentrations：
Incubation Time：
Powder Purity:≥99%
